Towards high-throughput light-activated drug discovery using automated plate illuminator

Robert Perttilä; John Roque III; Lasse Orsila; Zoe Ylöniemi; Elias Kokko; Colin G. Cameron; Sherri A. McFarland; Petteri Uusimaa

doi:10.1117/12.2578408

5 March 2021 Towards high-throughput light-activated drug discovery using automated plate illuminator

Robert Perttilä, John Roque III, Lasse Orsila, Zoe Ylöniemi, Elias Kokko, Colin G. Cameron, Sherri A. McFarland, Petteri Uusimaa

Author Affiliations +

Proceedings Volume 11628, Mechanisms and Techniques in Photodynamic Therapy and Photobiomodulation; 116280F (2021) https://doi.org/10.1117/12.2578408
Event: SPIE BiOS, 2021, Online Only

Abstract

There is an ongoing need in photodynamic therapy (PDT) research to develop highly active photosensitizers (PSs) with improved characteristics combined with optimized treatment protocols to produce effective treatment with minimal side effects. While several novel PSs have undergone clinical trials or been approved in recent years, there remain few available instrumentation options for high-throughput screens (HTS) with in vitro PDT. The Modulight ML8500 was developed to address this need, facilitating HTS of potential PSs with its precisely specific control over the light component. The instrument can select from a variety of high-power, monochromatic wavelengths for screening in the context of a tumor-centered approach, whereby the light dose can be tailored to optimize for physiological conditions or limitations specific to the type of cancer. In the present case, the ML8500 was used here to characterize a series of promising ruthenium-based complexes specifically designed to target melanoma. These PSs could be activated over a broad range of wavelengths, and most importantly including in the near-infrared range, where light penetrates tissue more effectively. In a second study, osmium-based PSs were characterized with the ML8500 in normoxic and hypoxic conditions with variable light parameters (wavelength, light dose, light fluence), showing high activity even in hypoxic conditions. These are specific examples where the ML8500 successfully increased experimental flexibility, reproducibility, and throughput.

Conference Presentation

Citation Download Citation

Robert Perttilä, John Roque III, Lasse Orsila, Zoe Ylöniemi, Elias Kokko, Colin G. Cameron, Sherri A. McFarland, and Petteri Uusimaa "Towards high-throughput light-activated drug discovery using automated plate illuminator", Proc. SPIE 11628, Mechanisms and Techniques in Photodynamic Therapy and Photobiomodulation, 116280F (5 March 2021); https://doi.org/10.1117/12.2578408

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available